Innovation in treatment

The site follows health and the risks that change it. Treatment is a key contributor and always comes with a start date: a drug is approved, an operation is first performed, a device is licensed. What follows is slower and less reported — whether it is paid for, whether it reaches beyond the centres that ran the trial, and whether the effect seen in the trial holds in the real world.

That gap is why this driver is not simply the sum of the disease pages. Transportability analysis is starting to put numbers on it. The same liraglutide trial, carried across to a US veteran population, produced a three-year benefit nearly three times the trial's own. A transcatheter valve trial, carried across to the Dutch registry, produced a substantially smaller impact.

The route the evidence takes is changing too, and faster than the treatments. Biosimilars are now approved on analytical and pharmacokinetic equivalence, without a comparative efficacy trial, which is how cheaper versions of expensive biologics arrive. Cost-effectiveness at launch is calculated from trial data and a model, and is almost never revisited once real use begins. Surgical and procedural innovation has no approval step at all. An operation enters practice through adoption, and the evidence, when it comes, always comes afterwards.

Trackers